Laura Musselwhite is a Hematology physician affiliated with Levine Cancer Institute. OpenAlex indexes 66 publications with 1,229 citations (h-index 15).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
100 Medical Park Dr
Ste 110
Concord, NC 280252948
Telephone
704-403-1370Registry record last updated 15 Jul 2024.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- SERVIER PHARMACEUTICALS LLCProgram year20233 payments
- AstraZeneca Pharmaceuticals LPProgram year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
31.5%Serotonin-3 Receptor Antagonist20.8%Ondansetron Hcl100%Part D≥42 patientsProton pump inhibitor3.9%Omeprazole100%Part D<11 patients+ 2 more classes in this area
Nervous system
26.7%Phenothiazine13.5%Prochlorperazine Maleate100%Part D≥29 patientsAtypical Antipsychotic5.9%Olanzapine100%Part D<11 patients+ 2 more classes in this area
Blood & clotting
18.8%Factor Xa inhibitor18.8%Eliquis100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Unveiling Discrepant and Rare Dihydropyrimidine Dehydrogenase (DPYD) Results Using an In-House Genotyping Test: A Case Series
Journal of the National Comprehensive Cancer Network
2024 - Addressing barriers to increased adoption of <i>DPYD</i> genotyping at a large multisite cancer center
American Journal of Health-System Pharmacy
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Peter Voorhees, MD
Levine Cancer Institute
Edward Copelan, MD
Levine Cancer Institute
Nilanjan Ghosh, MD
Levine Cancer Institute
Antoinette Tan, MD
Levine Cancer Institute
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”